RE: Awards2 Apr 2021 16:00
@Bravedog
So in 2019 "as a result of the Company’s strong TSR performance of 117% in the period from December 2016 to the second measurement date in April 2019, the maximum number of nil-cost options have been awarded to participants." We can probably presume that the prior grants "to the CEO and CFO of 1,681,839 nil-cost options each at the first measurement date in May 2018" vested but this should be confirmed. Just because the options have vested doesn't mean they have been exercised (see below).
They then "could only receive 2,087,756 and 1,565,817 nil-cost options respectively due to the cap in place" in 2019. Up to 50% of these could have vested in 2020 but didn't because the TSR was not met. The TSR will be tested again soon.
"The options outstanding at 31 December 2020 had a weighted average remaining contractual life of 2 years." One wouldn't exercise the options unless one wanted to sell the shares that you get from exercising them. There are only two ways that the company can meet the obligation to deliver shares pursuant to the exercise of an employee option. Either deliver existing shares that have been purchased (into treasury or held in an employee benefit trust) or issue new shares (diluting all shareholders). The recent pass announcement provides an example of doing a bit of each. I haven't looked to see if any shares were issued following the vesting that possibly took place in 2019 but will do so. The issuance of stock must be announced.
As for the TSR hurdle for the upcoming test, have you confirmed your listed threshold with the company?
(Opulentia is still living in the past. GKP died in 2016. Long live the new GKP.)
Happy Easter all